لا تُقدم XM خدماتها لمواطني الولايات المتحدة الأمريكية.
R
R

Roche


أخبار

Japan corporate earnings week ahead

DIARY-Japan corporate earnings week ahead Oct 18 (Reuters) - Diary of Japan (.N225) corporate earnings for the week ahead JAPAN EARNINGS Start Date Start Time(GMT) RIC Company Name Event Name 23-Oct-2024 06:15 6594.T Nidec Corp Q2 2025 Nidec Corp Earnings Release 24-Oct-2024 06:00 7751.T Canon Inc Q3 2024 Canon Inc Earnings Release 25-Oct-2024 08:00 4519.T Chugai Pharmaceutical Co Ltd Q3 2024 Chugai Pharmaceutical Co Ltd Earnings Release 25-Oct-2024 06:00 6954.T Fanuc Corp Q2 2025 Fanuc Corp Ear
R
J

Consumer groups ask FTC to block Novo Holdings-Catalent deal

UPDATE 2-Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing Adds comment from Novartis on Zolgensma in last paragraph By Jody Godoy and Maggie Fick NEW YORK, Oct 17 (Reuters) - U.S.
A
A
N
N
P
R

Consumer groups ask FTC to block Novo Holdings-Catalent deal

Consumer groups ask FTC to block Novo Holdings-Catalent deal Consumer groups and unions express competition concerns to FTC Deal could limit options for competitors developing GLP-1 drugs Concerns also raised about impact on gene therapy manufacturing By Jody Godoy, Maggie Fick NEW YORK, Oct 17 (Reuters) - Five U.S. consumer groups and two large labor unions urged the U.S.
A
A
N
N
P
R

Roche and Novartis topple Nestle in tight race

LIVE MARKETS-Roche and Novartis topple Nestle in tight race STOXX 600 up 0.6% TSMC beat, earnings provide support ECB in focus Banks lead gainers Nasdaq futures rise Welcome to the home for real-time coverage of markets brought to you by Reuters reporters. You can share your thoughts with us at markets.research@thomsonreuters.com ROCHE AND NOVARTIS TOPPLE NESTLE IN TIGHT RACE There is a tight race quietly unfolding in Zurich.
N
N
R
A
E
F
S
U
G

Swiss trade surplus at CHF 4.946 bln in September

TABLE-Swiss trade surplus at CHF 4.946 bln in September Oct 17 (Reuters) - Switzerland ran a merchandise trade surplus of 4.946 billion Swiss francs in September, the Federal Customs Office said on Thursday. KEY FIGURES (millions of Swiss francs) September 2024 August 2024 Imports 17.579 15.905 Exports 22.526 20.649 Balance 4.946 4.744 The figures exclude precious metals and stones, works of art and antiques.
C
L
N
R
R
S

Roche Holding Publishes Data Regarding Evrysdi Efficacy

BRIEF-Roche Holding Publishes Data Regarding Evrysdi Efficacy Oct 14 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE DATA CONFIRM EVRYSDI EFFICACY AND SAFETY IN CHILDREN FIRST TREATED PRE-SYMPTOMATICALLY BEFORE 6 WEEKS OF AGE, WITH MOST ACHIEVING MOTOR MILESTONES SIMILAR TO CHILDREN WITHOUT SMA Source text for Eikon: ID:nBw92GX3Ja Further company cov
R

Roche Receives FDA Approval For Itovebi

BRIEF-Roche Receives FDA Approval For Itovebi Oct 11 (Reuters) - ROCHE HOLDING AG ROG.S : FDA APPROVES ROCHE’S ITOVEBI, A TARGETED TREATMENT FOR ADVANCED HORMONE RECEPTOR-POSITIVE, HER2-NEGATIVE BREAST CANCER WITH A PIK3CA MUTATION ROCHE HOLDING AG - ITOVEBI REGIMEN DOUBLES PROGRESSION-FREE SURVIVAL IN PHASE III STUDY ROCHE HOLDING AG - ITOVEBI R
R

FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer

BRIEF-FDA Approves Inavolisib With Palbociclib & Fulvestrant For Endocrine-Resistant,Pik3ca-Mutated,Hr-Positive,Her2-Negative,Advanced Breast Cancer Oct 10 (Reuters) - FDA: FDA APPROVES INAVOLISIB WITH PALBOCICLIB AND FULVESTRANT FOR ENDOCRINE-RESISTANT, PIK3CA-MUTATED, HR-POSITIVE, HER2-NEGATIVE, ADVANCED BREAST CANCER FDA: APPROVED FOUNDATIONONE
R

Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study

BUZZ-Tempest Therapeutics jumps on agreement with Roche to advance liver cancer drug study ** Shares of drug developer Tempest Therapeutics TPST.O up 19.21% at $1.60 premarket ** TPST to conduct a late-stage study of its experimental drug amezalpat, in combination with Swiss drugmaker Roche's ROG.S Tecentriq and bevacizumab, for the treatment of me
R

Roche Obtains CE Certification For Companion Diagnostic

BRIEF-Roche Obtains CE Certification For Companion Diagnostic Oct 10 (Reuters) - ROCHE HOLDING AG ROG.S : OBTAINS CE CERTIFICATION FOR THE FIRST COMPANION DIAGNOSTIC TO IDENTIFY PATIENTS WITH GASTRIC AND GASTROESOPHAGEAL JUNCTION CANCER ELIGIBLE FOR TARGETED TREATMENT WITH VYLOY Source text for Eikon: ID:nGNE1TDGf7 Further company coverage: ROG.S (
R

Roche CEO: breast cancer pill could enter $12 bln market if trials succeed

UPDATE 1-Roche CEO: breast cancer pill could enter $12 bln market if trials succeed Adds background from paragraph 2 By Ludwig Burger MANNHEIM, Germany, Oct 9 (Reuters) - Roche's ROG.S experimental oral drug for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($12 billion) a year if it clears two key trials on early treatment of the disease, the Swiss drugmaker's CEO said.
A
R
S

Roche CEO: breast cancer pill could be in 10 bln CHF market if trials succeed

Roche CEO: breast cancer pill could be in 10 bln CHF market if trials succeed FRANKFURT, Oct 9 (Reuters) - Roche's ROG.S CEO said on Wednesday that the Swiss drugmaker's oral drug candidate for breast cancer giredestrant could enter a market worth at least 10 billion Swiss francs ($11.66 billion) annually if it succeeds in two key trials on early treatment of the disease.
R

Scholar Rock shares jump 300% after rare disease drug scores trial win

UPDATE 3-Scholar Rock shares jump 300% after rare disease drug scores trial win Adds analyst comments in paragraphs 6 and 7, similar drugs in paragraphs 5 and 8, updates shares By Christy Santhosh Oct 7 (Reuters) - Scholar Rock's SRRK.O experimental drug achieved its main target in a late-stage trial for spinal muscular atrophy, the biotech company said on Monday, sending its shares soaring more than 300% in early trading.
B
N
R

WHO approves first mpox diagnostic test for emergency use

UPDATE 4-WHO approves first mpox diagnostic test for emergency use Updates Oct. 3 story to add company statement in paragraph 4 Oct 3 (Reuters) - The World Health Organization authorized Abbott Laboratories' ABT.N mpox diagnostic test for emergency use on Thursday, the first such approval in the agency's effort to bolster testing capabilities in countries facing outbreaks of the disease.
A
R
L

Financial Times - Oct 1

PRESS DIGEST- Financial Times - Oct 1 Oct 1 (Reuters) - The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy. Headlines - Simon Case steps down as UK cabinet secretary - EY picks Anna Anthony as UK boss after three-way race - Roche plans to launch drugs and slash development costs - LVMH sells Off-White streetwear brand founded by Virgil Abloh - Qatar Airways agrees to buy 25% stake in Virgin Australia Overview Sim
L
R

Roche targets more than $3 billion in annual obesity sales

UPDATE 1-Roche targets more than $3 billion in annual obesity sales Releads By Ludwig Burger FRANKFURT, Sept 30 (Reuters) - Roche ROG.S said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 billion) in annual sales . In a presentation to investors, the Swiss drugmaker said the revenue projection applies on aggregate to weekly injection CT-388 - which is similar t
R

Roche aims to slash drug development time and costs by 2030

Roche aims to slash drug development time and costs by 2030 FRANKFURT, Sept 30 (Reuters) - Swiss drugmaker Roche ROG.S said on Monday it aims to slash the development costs of drugs it brings to market and speed up their development time by 2030. Average development costs of a drug that is launched should decline by 20% and the time from early drug discovery to the end of Phase 3 testing on humans would be cut by 40%, according to presentation slides posted on the company's website.
R

Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Positive Phase III Results For Genentech’S Gazyva Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - Roche Holding AG ROG.S : POSITIVE PHASE III RESULTS FOR GENENTECH’S GAZYVA SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS Source text for Eikon: ID:nBw2HSqmRa Further co
R

Vontobel raises Roche to 'buy' ahead of expected strategy update

BUZZ-Vontobel raises Roche to 'buy' ahead of expected strategy update ** Vontobel raises Roche ROG.S to "buy" from "hold" based on the Swiss drugmaker's planned R&D cost controls and ahead of its expected strategy update at the end of the month ** The company's Pharma Day on Sept. 30 is the key event to understanding how the new leadership will run
R

Roche Says Positive Phase III Results For Gazyva/Gazyvaro Show Superiority To Standard Therapy Alone In People With Lupus Nephritis

BRIEF-Roche Says Positive Phase III Results For Gazyva/Gazyvaro Show Superiority To Standard Therapy Alone In People With Lupus Nephritis Sept 26 (Reuters) - ROCHE HOLDING AG ROG.S : POSITIVE PHASE III RESULTS FOR ROCHE’S GAZYVA/GAZYVARO SHOW SUPERIORITY TO STANDARD THERAPY ALONE IN PEOPLE WITH LUPUS NEPHRITIS REGENCY STUDY MET ITS PRIMARY ENDPOI
R



الشروط

الأصول الشائعة

إخلاء المسؤولية: تتيح كيانات XM Group خدمة تنفيذية فقط والدخول إلى منصة تداولنا عبر الإنترنت، مما يسمح للشخص بمشاهدة و/أو استخدام المحتوى المتاح على موقع الويب أو عن طريقه، وهذا المحتوى لا يراد به التغيير أو التوسع عن ذلك. يخضع هذا الدخول والاستخدام دائماً لما يلي: (1) الشروط والأحكام؛ (2) تحذيرات المخاطر؛ (3) إخلاء المسؤولية الكامل. لذلك يُقدم هذا المحتوى على أنه ليس أكثر من معلومات عامة. تحديداً، يرجى الانتباه إلى أن المحتوى المتاح على منصة تداولنا عبر الإنترنت ليس طلباً أو عرضاً لدخول أي معاملات في الأسواق المالية. التداول في أي سوق مالي به مخاطرة عالية برأس مالك.

جميع المواد المنشورة على منصة تداولنا مخصصة للأغراض التعليمية/المعلوماتية فقط ولا تحتوي - ولا ينبغي اعتبار أنها تحتوي - على نصائح أو توصيات مالية أو ضريبية أو تجارية، أو سجلاً لأسعار تداولنا، أو عرضاً أو طلباً لأي معاملة في أي صكوك مالية أو عروض ترويجية مالية لا داعي لها.

أي محتوى تابع للغير بالإضافة إلى المحتوى الذي أعدته XM، مثل الآراء، والأخبار، والأبحاث، والتحليلات والأسعار وغيرها من المعلومات أو روابط مواقع تابعة للغير وواردة في هذا الموقع تُقدم لك "كما هي"، كتعليق عام على السوق ولا تعتبر نصيحة استثمارية. يجب ألا يُفسر أي محتوى على أنه بحث استثماري، وأن تلاحظ وتقبل أن المحتوى غير مُعدٍ وفقاً للمتطلبات القانونية المصممة لتعزيز استقلالية البحث الاستثماري، وبالتالي، فهو بمثابة تواصل تسويقي بموجب القوانين واللوائح ذات الصلة. فضلاً تأكد من أنك قد قرأت وفهمت الإخطار بالبحوث الاستثمارية غير المستقلة والتحذير من مخاطر المعلومات السابقة، والذي يمكنك الاطلاع عليه هنا.

تحذير المخاطر: رأس مالك في خطر. المنتجات التي تستخدم الرافعة قد لا تكون مناسبة للجميع. يرجى الاطلاع على تنبيه المخاطر.